Clinical trial
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas…
NCT00276783 · Northwestern University, Other · Unknown status
Key facts
| NCT number | NCT00276783 |
|---|---|
| Title | Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases |
| Official title | A Phase II Trial of Alimta (Pemetrexed) in Patients With Recurrent Malignant Gliomas, Primary Central Nervous System Lymphoma, and Brain Metastases |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed |
| Enrollment | 31 |
| Start date | Nov 1, 2005 |
| Primary completion | Dec 1, 2022 |
| Completion | Dec 1, 2022 |
| First posted | Jan 13, 2006 |
| Last update posted | Mar 5, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: